DiamiR Announces Presentation at the 2014 BIO International Convention

MONMOUTH JUNCTION, NJ--(Marketwired - June 18, 2014) - DiamiR, LLC, a molecular diagnostics company focused on the development and commercialization of innovative tests for detection and monitoring of neurodegenerative diseases and cancer based on analysis of organ-enriched microRNA biomarker pairs in plasma, announced today that the company's CEO, Dr. Kira Sheinerman, will be presenting at the 2014 BIO International Convention in San Diego, CA.

Date: Tuesday, June 24
Time: 10:15 am PDT
Location: San Diego Convention Center, San Diego, CA
Room: Imperial Beach

About microRNAs as biomarkers of brain health

microRNAs (miRNAs) are a class of non-coding functional RNA molecules modulating target gene expression and protein production. Many miRNAs are enriched in certain organs (e.g. brain), tissues or organ regions (e.g. hippocampus, midbrain), cell types (e.g. neurons), and cellular compartments (e.g. synapses and neurites). Due to their small size (~22 nucleotides), miRNAs can cross the blood-brain barrier and appear in the bloodstream. Thus, the properties of brain-enriched miRNAs make them powerful and patient friendly biomarkers of brain health.

About DiamiR, LLC

DiamiR, LLC is a privately held molecular diagnostic company focused on developing noninvasive tests for early detection and monitoring of Mild Cognitive Impairment, Alzheimer's disease, other neurodegenerative diseases, and cancer. The proprietary technology is based on quantitative analysis of circulating organ-enriched miRNAs in plasma and can be used for screening, patient stratification as well as disease and treatment monitoring. For more information, please visit the company's website at www.diamirbio.com.

Please Note: This news release contains forward-looking statements regarding future events. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include, among others: the results, timing, costs and regulatory review of our studies and clinical trials; the results of studies of our product candidates conducted by others; our ability to obtain future funding on acceptable terms; our ability to obtain regulatory approval of our product candidates; the possible impairment of, or inability to obtain, intellectual property rights; and innovation by our competitors.